XClose

UCL Department of Biochemical Engineering

Home
Menu

Vaccine Bioprocess Development and Commercialisation

Delivered in collaboration with Massachusetts Institute of Technology (MIT), this course will assist in developing your knowledge on the challenges of creating a vaccine process.

This course will explore the critical issues at the various stages of vaccine development. International experts with over 10 years’ experience in their field will lead delegates in developing their understanding in the research, development, operational and regulatory challenges of the vaccine market. In addition to expert lectures and excellent networking opportunities with your peers, one case study will be conducted during the workshop about manufacturing at-risk with real examples from the influenza manufacturing process.

Topics covered will include:
• Scale-up from lab to pilot scale.
• Quality by Design (QbD) as part of vaccine development.
• Expression systems.
• Single use platforms.
• Regulation and its impact on development.
• Final formulation and adjuvants.
• Developing world needs.

This MBI is recommended for:

This course is of interest to research scientists, programme managers, process engineers and policy makers. The course is accessible to those new to vaccine development or those working in the field from business and academia.

• Specialised vaccines staff who would benefit from broadening their knowledge base
• Those new to vaccine development (recent graduates / research scientists)
• Project Managers, funders and policy-makers wanting to gain an understanding in vaccines.

Module Leader

Stefanie is a Lecturer in Synthetic Biology at the Department of Biochemical Engineering at University College London (UCL). She graduated with a PhD in Biochemistry from Queen Mary University of London. During her postdoctoral training and as a Leverhulme Early Career Fellow at the University of Kent she largely focused on the characterisation and engineering of bacterial protein microcompartments for the construction of novel nano-bioreactors. Since then Stefanie’s work has moved on to molecular design of virus-like particle vaccines (e.g. foot-and-mouth disease) and structure-product analytics as part of a multidisciplinary team of the UCL/Oxford-led Future Vaccine Manufacturing Research Hub (Vax-Hub) which works to address major challenges facing vaccine manufacturing and deployment. In addition, Stefanie is part of a Global Challenges Research Fund project with Thailand supporting the yeast bioprocess development for the production of animal vaccine against porcine circovirus. She is also investigating bacterial nano-compartments as modular platforms for cancer immunotherapy